Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 155 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Transcriptome analysis Clear all
Terminated Phase 2 Interventional Results available

Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma

NCT00942422
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Interventions
defined green tea catechin extract, gene expression analysis, protein analysis, laboratory biomarker analysis
Dietary Supplement · Genetic · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Sep 2, 2026, 2:21 AM EDT
Completed No phase listed Observational

S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00450281
View directory record Official record
Conditions
Lung Cancer
Interventions
chromogenic in situ hybridization, gene expression analysis, mutation analysis, polymerase chain reaction, polymorphism analysis, fluorescent antibody technique, immunohistochemistry staining method, laboratory biomarker analysis, matrix-assisted laser desorption/ionization time of flight mass spectrometry, study of socioeconomic and demographic variables, study of high risk factors
Genetic · Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
981 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
405
States / cities
Anchorage, Alaska • Tucson, Arizona • Fort Smith, Arkansas + 279 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2015 · Synced Sep 2, 2026, 2:21 AM EDT
Terminated No phase listed Observational

Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer

NCT00899197
View directory record Official record
Conditions
Breast Cancer
Interventions
tamoxifen citrate, gene expression analysis, protein expression analysis, immunoenzyme technique, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 2, 2026, 2:21 AM EDT
Completed Phase 1 Interventional

Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

NCT00816283
View directory record Official record
Conditions
Leukemia
Interventions
dasatinib, vorinostat, cytogenetic analysis, gene expression analysis, mutation analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Sep 2, 2026, 2:21 AM EDT
Terminated Phase 2 Interventional Results available

UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas

NCT00082017
View directory record Official record
Conditions
Lymphoma, Large-Cell, Ki-1, Lymphoma, T-Cell
Interventions
UCN-01 (7-hydroxystaurosporine)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 2, 2026, 2:21 AM EDT
Completed No phase listed Observational

Study of Biomarkers in Blood & Tissue Samples From Patients With Colorectal Cancer or Polyps & Patients Without Polyps

NCT00898378
View directory record Official record
Conditions
Colorectal Cancer, Healthy, no Evidence of Disease, Precancerous Condition
Interventions
gene expression analysis, polymerase chain reaction, polymorphism analysis, protein expression analysis, proteomic profiling, gas chromatography, laboratory biomarker analysis, liquid chromatography, mass spectrometry, questionnaire administration
Genetic · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Sep 2, 2026, 2:21 AM EDT
Completed Phase 1 Interventional

Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors

NCT00389922
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
lapatinib ditosylate, Vinorelbine ditartrate, comparative genomic hybridization, cytogenetic analysis, gene expression analysis, mutation analysis, polymerase chain reaction, polymorphism analysis, proteomic profiling, reverse transcriptase-polymerase chain reaction, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
4
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Sep 2, 2026, 2:21 AM EDT
Completed No phase listed Observational

Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma

NCT00617799
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin)
Interventions
aldesleukin, gene expression analysis, mutation analysis, flow cytometry
Biological · Genetic · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 2, 2026, 2:21 AM EDT
Terminated Phase 2 Interventional Results available

Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy

NCT00390364
View directory record Official record
Conditions
Colorectal Cancer
Interventions
everolimus, antiangiogenesis therapy, biopsy, diagnostic procedure, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, mutation analysis, protein tyrosine kinase inhibitor therapy, reverse transcriptase-polymerase chain reaction
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Sep 2, 2026, 2:21 AM EDT
Terminated Phase 2 Interventional Results available

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

NCT00665457
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, capecitabine, celecoxib, cyclophosphamide, docetaxel, doxorubicin hydrochloride, gene expression analysis, polymorphism analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, imaging biomarker analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacogenomic studies, dynamic contrast-enhanced magnetic resonance imaging, needle biopsy, neoadjuvant therapy, radiomammography, ultrasound imaging
Biological · Drug · Genetic + 2 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 2, 2026, 2:21 AM EDT
Completed Phase 2 Interventional

Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment

NCT00673569
View directory record Official record
Conditions
Lung Cancer
Interventions
erlotinib hydrochloride, gene expression analysis, protein expression analysis, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, needle biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2010 · Synced Sep 2, 2026, 2:21 AM EDT
Terminated Phase 2 Interventional

Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

NCT00323791
View directory record Official record
Conditions
Kidney Cancer
Interventions
gemcitabine hydrochloride, imatinib mesylate, gene expression analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Sep 2, 2026, 2:21 AM EDT
Completed Phase 1 Interventional

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors

NCT00423865
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cisplatin, everolimus, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Sep 2, 2026, 2:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

NCT01075321
View directory record Official record
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions
everolimus, lenalidomide, laboratory biomarker analysis, polymorphism analysis, immunohistochemistry staining method, microarray analysis, fluorescence in situ hybridization
Drug · Other · Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 2, 2026, 2:21 AM EDT
Completed No phase listed Observational

Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia

NCT01284010
View directory record Official record
Conditions
Leukemia
Interventions
DNA analysis, fluorescence in situ hybridization, gene expression analysis, microarray analysis, mutation analysis, polymerase chain reaction, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 2, 2026, 2:21 AM EDT
Not listed No phase listed Observational

Molecular Biomarkers in Renal Transplantation Via TruGraf® Test

NCT04398498
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Diagnostic Test: TruGraf® Testing
Diagnostic Test
Lead sponsor
Transplant Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Sep 2, 2026, 2:21 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

NCT01336933
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma
Interventions
prednisone, cyclophosphamide, etoposide, Vincristine, pralatrexate, laboratory biomarker analysis, comparative genomic hybridization, gene expression analysis, nucleic acid sequencing, mutation analysis, immunohistochemistry staining method, microarray analysis, RNA analysis
Drug · Other · Genetic
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
9
States / cities
Scottsdale, Arizona • Stanford, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Sep 2, 2026, 2:21 AM EDT
Completed Phase 1 Interventional

Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer

NCT00379509
View directory record Official record
Conditions
Breast Cancer
Interventions
lapatinib ditosylate, TdT-mediated dUTP nick end labeling assay, gene expression analysis, microarray analysis, immunohistochemistry staining method, biopsy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 2, 2026, 2:21 AM EDT
Terminated Phase 2 Interventional Results available

Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

NCT00851552
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bortezomib, pegylated liposomal doxorubicin hydrochloride, gene expression analysis, polymerase chain reaction, polymorphism analysis, proteomic profiling, flow cytometry, laboratory biomarker analysis
Biological · Drug · Genetic + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2014 · Synced Sep 2, 2026, 2:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma

NCT00233948
View directory record Official record
Conditions
Adult Liposarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
nelfinavir mesylate, biopsy, laboratory biomarker analysis, pharmacological study, gene expression analysis, western blotting, reverse transcriptase-polymerase chain reaction, immunoenzyme technique
Drug · Procedure · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Sep 2, 2026, 2:21 AM EDT
Completed Phase 2 Interventional Results available

Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma

NCT01177735
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Sep 2, 2026, 2:21 AM EDT
Withdrawn Phase 1 Interventional

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

NCT01332279
View directory record Official record
Conditions
Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Tongue Cancer
Interventions
everolimus, erlotinib hydrochloride, biopsy, laboratory biomarker analysis, immunohistochemistry staining method, polyacrylamide gel electrophoresis, pharmacological study, external beam radiation therapy, microarray analysis
Drug · Procedure · Other + 2 more
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 2, 2026, 2:21 AM EDT
Not listed Phase 2 Interventional

Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer

NCT00717587
View directory record Official record
Conditions
Kidney Cancer
Interventions
motexafin gadolinium, sunitinib malate, comparative genomic hybridization, gene expression analysis, mutation analysis, polymorphism analysis, immunohistochemistry staining method, iodine I-124 girentuximab, laboratory biomarker analysis, pharmacological study, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Sep 2, 2026, 2:21 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection Early Post-transplantation

NCT00962377
View directory record Official record
Conditions
Graft Rejection, Heart Diseases
Interventions
Endomyocardial biopsy, AlloMap Molecular Testing
Procedure
Lead sponsor
XDx
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2010 · Synced Sep 2, 2026, 2:21 AM EDT